

References (Part I)

- Abrams, D. I. (2016). Integrating cannabis into clinical cancer care. *Current Oncology*, 23, 8-14.
- Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., ... & Deeks, S. G. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. *Annals of Internal Medicine*, 139(4), 258-266.
- Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., ... & Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*, 68(7), 515-521.
- Aggarwal, S. K. (2016). Use of cannabinoids in cancer care: Palliative care. *Current Oncology*, 23, 33-36.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Washington, DC: Author.
- Anderson, D. M., Hansen, B., & Rees, D. I. (2013). Medical marijuana laws, traffic fatalities, and alcohol consumption. *The Journal of Law and Economics*, 56(2), 333-369.
- Andries, A., Frystyk, J., Flyvbjerg, A., & Støving, R. K. (2014). Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial. *International Journal of Eating Disorders*, 47(1), 18-23.
- Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., ... & Inghilleri, M. (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. *Clinical Neuropharmacology*, 32(1), 41-47.
- Arizona Department of Health Services. (2016). *Arizona Medical Marijuana Program 2016 Fiscal Year-End Report*. Retrieved from <http://azdhs.gov/documents/licensing/medical-marijuana/reports/2016/mm-fy16-year-end-report.pdf>
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Internal Medicine*, 174(10), 1668-1673.
- Baethge, C., Hennen, J., Khalsa, H. M. K., Salvatore, P., Tohen, M., & Baldessarini, R. J. (2008). Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. *Bipolar Disorders*, 10(6), 738-741.
- Baker, T., Datta, P., Rewers-Felkins, K., Thompson, H., Kalle, R. R., & Hale, T. W. (2018). Transfer of inhaled cannabis into human breast milk. *Obstetrics & Gynecology*, 131(5), 783-788.
- Beek v. City of Wyoming*. (2014, February 6) (Findlaw, Dist. 145816). Retrieved from <http://caselaw.findlaw.com/mi-supreme-court/1656759.html>
- Berlin, J. A., & Golub, R. M. (2014). Meta-analysis as evidence: Building a better pyramid. *JAMA*, 312(6), 603-606.
- Bernstein, L. (2016, August 11). U.S. affirms its prohibition on medical marijuana. *The Washington Post*. Retrieved from <https://www.washingtonpost.com/news/to-your-health/wp/2016/08/10/u-s-affirms-its-prohibition-on-medical-marijuana/>
- Bestrashniy, J., & Winters, K. C. (2015). Variability in medical marijuana laws in the United States. Psychology of addictive behaviors. *Journal of the Society of Psychologists in Addictive Behaviors*, 29(3), 639-642.
- Bisaga, A., Sullivan, M. A., Glass, A., Mishlen, K., Pavlicova, M., Haney, M., ... & Nunes, E. V. (2015). The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. *Drug and Alcohol Dependence*, 154, 38-45.
- Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology*, 45(1), 50-52.
- Boehnke, K. F., & Litinas, E., Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *The Journal of Pain*, 17(6), 739-744.
- Bonn-Miller, M. O., Loflin, M. J., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. *JAMA*, 318(17), 1708-1709.
- Calabria, B., Degenhardt, L., Hall, W., & Lynskey, M. (2010). Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug and Alcohol Review*, 29(3), 318-330.
- Caldeira, K. M., Arria, A. M., O'Grady, K. E., Vincent, K. B., & Wish, E. D. (2008). The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students. *Addictive Behaviors*, 33(3), 397-411.
- Campbell, C. T., Phillips, M. S., & Manasco, K. (2017). Cannabinoids in pediatrics. *The Journal of Pediatric Pharmacology and Therapeutics*, 22(3), 176-185.
- Cao, D., Srisuma, S., Bronstein, A. C., & Hoyte, C. O. (2016). Characterization of edible marijuana product exposures reported to United States poison centers. *Clinical Toxicology*, 54(9), 840-846.
- Carrà, G., Bartoli, F., Crocamo, C., Brady, K. T., & Clerici, M. (2014). Attempted suicide in people with co-occurring bipolar and substance use disorders: Systematic review and meta-analysis. *Journal of Affective Disorders*, 167, 125-135.
- Chen, A. (2017, April 20). Some of the Parts: Is marijuana's "entourage effect" scientifically valid? (2017, April 20). *Scientific American*. Retrieved from <https://www.scientificamerican.com/article/some-of-the-parts-is-marijuana-s-ldquo-entourage-effect-rdquo-scientifically-valid/>
- Chen, C. Y., Storr, C. L., & Anthony, J. C. (2009). Early-onset drug use and risk for drug dependence problems. *Addictive Behaviors*, 34(3), 319-322.
- Cochrane Methods Bias. (n.d.). *Assessing risk of bias in included studies*. Retrieved from <http://methods.cochrane.org/bias/assessing-risk-bias-included-studies>
- Collin, C., Davies, P., Mutiboko, I. K., & Ratcliffe, S. (2007). Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *European Journal of Neurology*, 14(3), 290-296.

- Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., ... & Zapletalova, O. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurological Research*, 32(5), 451-459.
- Colorado Department of Public Health & Environment. (2016). *Medical Marijuana Registry Program Statistics December 31, 2016*. Retrieved from https://www.colorado.gov/pacific/sites/default/files/CHED_MMR_Report_December_2016.pdf
- Colorado Department of Revenue. (2015, August 10). *Marijuana equivalency in portion and dosage*. Retrieved from https://www.colorado.gov/pacific/sites/default/files/MED%20Equivalency_Final%2008102015.pdf Compassionate Use Act of 1996, Cal. Health and Safety Code § 11362.5 (1996).
- Comprehensive Drug Abuse Prevention and Control Act, 21 U.S.C. § 801 – 904 (1970).
- Cooper, Z. D., Comer, S. D., & Haney, M. (2013). Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. *Neuropsychopharmacology*, 38(10), 1984-1992.
- Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012). Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebo-controlled trial. *Canadian Medical Association Journal*, 184(10), 1143-1150.
- Cougle, J. R., Bonn-Miller, M. O., Vujanovic, A. A., Zvolensky, M. J., & Hawkins, K. A. (2011). Posttraumatic stress disorder and cannabis use in a nationally representative sample. *Psychology of Addictive Behaviors*, 25(3), 554.
- Crean, R. D., Crane, N. A., & Mason, B. J. (2011). An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. *Journal of Addiction Medicine*, 5(1), 1.
- Curtis, A., & Rickards, H. (2006). Nabilone could treat chorea and irritability in Huntington's disease. *The Journal of Neuropsychiatry and Clinical Neurosciences*, 18(4), 553-554.
- de Graaf, M. (2017, January). Marijuana DOES cause schizophrenia and triggers heart attacks, experts say in landmark study that slams most of the drug's medical benefits as 'unproven.' *The Daily Mail*. Retrieved from <http://www.dailymail.co.uk/health/article-4114634/Marijuana-DOES-cause-schizophrenia-triggers-heart-attacks-experts-say-landmark-study-slams-drug-s-medical-benefits-unproven.html>
- Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabhout, R., & Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *New England Journal of Medicine*, 376(21), 2011-2020.
- di Giacomo, D., De Domenico, E., Sette, C., Geremia, R., & Grimaldi, P. (2016). Type 2 cannabinoid receptor contributes to the physiological regulation of spermatogenesis. *The FASEB Journal*, 30(4), 1453-1463.
- Drug Enforcement Administration (DEA). (2014). *Disposal Act: General Public Fact Sheet*. Retrieved from https://www.deadiversion.usdoj.gov/drug_disposal/fact_sheets/disposal_public.pdf
- Drug Enforcement Administration (DEA). (2016, August 12). 81 FR 53688. Denial of Petition to Initiate Proceedings to Reschedule Marijuana. Retrieved from www.gpo.gov/fdsys/granule/FR-2016-08-12/2016-17954.
- Drug Enforcement Administration (DEA). (2017, November 8). *Established aggregate production quotas for Schedule I and II controlled substances and assessment of annual needs for the List I chemicals ephedrine, pseudo-ephedrine, and phenylpropranolamine for 2018*. 82 FR 51873. Retrieved from <https://www.federalregister.gov/documents/2017/11/08/2017-24306/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment>
- du Plessis, S. S., Agarwal, A., & Syriac, A. (2015). Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. *Journal of Assisted Reproduction and Genetics*, 32(11), 1575-1588.
- Ellis, R. J., Toperoff, W., Vaida, F., Van Den Brande, G., Gonzales, J., Gouaux, B., ... & Atkinson, J. H. (2009). Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology*, 34(3), 672-680.
- Food and Drug Administration. (2004, September). *Marinol (dronabinol) capsules*. Retrieved from <https://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf>
- Food and Drug Administration. (2006, May). *Cesamet (nabilone) capsules*. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011bl.pdf
- Food and Drug Administration. (2017, August). *Marinol (dronabinol) capsules*. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s0291bl.pdf
- Food and Drug Administration. (2017, November 1). *FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer*. Retrieved from <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583295.htm>
- Filloux, F. M. (2015). Cannabinoids for pediatric epilepsy? Up in smoke or real science? *Translational Pediatrics*, 4(4), 271.
- Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., ... & Kamerman, P. R. (2015). Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. *The Lancet Neurology*, 14(2), 162-173.
- Fox, P., Bain, P. G., Glickman, S., Carroll, C., & Zajicek, J. (2004). The effect of cannabis on tremor in patients with multiple sclerosis. *Neurology*, 62(7), 1105-1109.
- Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N. S., & Kapur, D. (2008). Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. *BMJ*, 336(7637), 199-201.
- Freeman, R. M., Adekanmi, O., Waterfield, M. R., Waterfield, A. E., Wright, D., & Zajicek, J. (2006). The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo-controlled trial (CAMS-LUTS). *International Urogynecology Journal*, 17(6), 636-641.
- Freeman, T. P., & Winstock, A. R. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. *Psychological Medicine*, 45(15), 3181-3189.
- Gibbs, M., Winsper, C., Marwaha, S., Gilbert, E., Broome, M., & Singh, S. P. (2015). Cannabis use and mania symptoms: A systematic review and meta-analysis. *Journal of Affective Disorders*, 171, 39-47.
- Glass, M., Faull, R. L. M., & Dragunow, M. (1997). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*, 77(2), 299-318.
- Government of Canada. (2016, August). *Understanding the new access to cannabis for medical purposes regulations*. Retrieved from <https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html>
- Greenberg, H. S., Werness, S. A., & Pugh, J. E., Andrus, R. O., Anderson, D. J., & Domino, E. F. (1994). Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clinical Pharmacology and Therapeutics*, 55(3), 324-328.
- Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical Pharmacokinetics*, 42(4), 327-360.
- Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M. T., Smith, R. T., & Lukas, S. E. (2016). Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. *Frontiers in Pharmacology*, 7, 355.

- Gunn, J. K. L., Rosales, C. B., Center, K. E., Nuñez, A., Gibson, S. J., Christ, C., & Ehiri, J. E. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. *BMJ Open*, 6(4), e009986. Retrieved from <http://bmjopen.bmj.com/content/6/4/e009986>
- Gupta, S. (2014, March 11). Medical marijuana and 'the entourage effect.' Retrieved from www.cnn.com/2014/03/11/health/gupta-marijuana-entourage/index.html
- Gutierrez, G., & Dubert, M. (2017, November 30). *Marijuana may hold promise in treating veterans with PTSD*. Retrieved from <https://www.nbcnews.com/nightly-news/marijuana-may-hold-promise-treating-veterans-ptsd-n824956>
- GW's Epidiolex® Clinical Program. (2018). Retrieved from <https://www.gwpharm.com/epilepsy-patients-caregivers/patients>
- GW Pharmaceuticals. (2015, April 22). GW Pharmaceuticals announces new physician reports of Epidiolex® treatment effect in children and young adults with treatment-resistant epilepsy. *GW Pharmaceuticals*. Retrieved from <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=908097>
- Hall, W., & Solowij, N. (1998). Adverse effects of cannabis. *The Lancet*, 352(9140), 1611-1616.
- Hallak, J. E., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C., Chaves, C., ... & Zuardi, A. W. (2010). Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). *Revista Brasileira de Psiquiatria*, 32(1), 56-61.
- Halperin, A. (2016, October 29). After the election, marijuana could be legal for recreational or medical use in 29 states. *Los Angeles Times*. Retrieved from <http://www.latimes.com/politics/la-na-pol-marijuana-initiatives-snap-story.html>
- Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2007). Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep. *Journal of Acquired Immune Deficiency Syndromes*, 45(5), 545-554.
- Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W. (2005). Dronabinol and marijuana in HIV+ marijuana smokers: Acute effects on caloric intake and mood. *Psychopharmacology*, 181(1), 170-178.
- Haug, N. A., Kieschnick, D., Sottile, J. E., Babson, K. A., Vandrey, R., & Bonn-Miller, M. O. (2016). Training and practices of cannabis dispensary staff. *Cannabis and Cannabinoid Research*, 1(1), 244-251.
- Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J., & Verpoorte, R. (2006). Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. *Journal of Pharmaceutical Sciences*, 95(6), 1308-1317.
- Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., & Grotenhermen, F. (2013). The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms. *Journal of Psychoactive Drugs*, 45(3), 199-210.
- Health Canada. (2013). *Information for health care professionals: Cannabis (marijuana, marijuana) and the cannabinoids*. Ottawa, Ontario: Government of Canada.
- Health Canada. (2016). *A framework for the legalization and regulation of cannabis in Canada* (Publication No. 160248). Ottawa, Ontario: Government of Canada.
- Herning, R. I., Hooker, W. D., & Jones, R. T. (1986). Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology*, 90(2), 160-162.
- Hesse, M., & Thylstrup, B. (2013). Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers. *BMC Psychiatry*, 13(1), 258.
- Hickey, W. (2014, April 29). *Medical marijuana is still the best deal on pot in Colorado*. Retrieved from <https://fivethirtyeight.com/features/medical-marijuana-is-still-the-best-deal-in-colorado/>
- Ishida, J. H., Peters, M. G., Jin, C., Louie, K., Tan, V., Bacchetti, P., & Terrault, N. A. (2008). Influence of cannabis use on severity of hepatitis C disease. *Clinical Gastroenterology and Hepatology*, 6(1), 69-75.
- Is it cheaper to buy weed on the street or at a dispensary?* (2016, February 3). Retrieved from <https://priceonomics.com/the-most-expensive-and-cheapest-cities-to-buy/>
- Jaques, S. C., Kingsbury, A., Henschke, P., Chomchai, C., Clews, S., Falconer, J., ... & Oei, J. L. (2014). Cannabis, the pregnant woman and her child: Weeding out the myths. *Journal of Perinatology*, 34(6), 417.
- Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology*, 51, 585-588.
- Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. *Journal of Pain and Symptom Management*, 39(2), 167-179.
- Jones, R. T., Benowitz, N. L., & Herning, R. I. (1981). Clinical relevance of cannabis tolerance and dependence. *The Journal of Clinical Pharmacology*, 21(S1).
- Joseph, A. (2017, July 24). U.S. Called for New Marijuana Research Bids—but Granted No Approvals. Retrieved from: <https://www.scientificamerican.com/article/u-s-called-for-new-marijuana-research-bids-but-granted-no-approvals/>
- Joy, J. E., Watson, S. J., Benson, J. A. (Eds.). (1999). *Marijuana and medicine: Assessing the science base*. Washington, DC: National Academies Press.
- Jutras-Aswad, D., DiNieri, J. A., Harkany, T., & Hurd, Y. L. (2009). Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. *European Archives of Psychiatry and Clinical Neuroscience*, 259(7), 395-412.
- Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. *Clinical Pharmacology & Therapeutics*, 89(3), 400-407.
- Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003). Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. *JAMA*, 290(13), 1757-1762.
- Katona, I. (2015). Cannabis and endocannabinoid signaling in epilepsy. In R. G. Pertwee (ed.). *Endocannabinoids* (pp. 285-316). Springer International Publishing.
- Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. *Multiple Sclerosis Journal*, 16(11), 1349-1359.
- Kelley, M. E., Wan, C. R., Broussard, B., Crisafio, A., Cristofaro, S., Johnson, S., ... & Compton, M. T. (2016). Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. *Schizophrenia Research*, 171(1), 62-67.
- Kondrad, E., & Reid, A. (2013). Colorado family physicians' attitudes toward medical marijuana. *The Journal of the American Board of Family Medicine*, 26(1), 52-60.
- Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014). Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*, 82(17), 1556-1563.

- Kowal, M. A., Hazekamp, A., & Grotenhermen, F. (2016). Review on clinical studies with cannabis and cannabinoids 2010-2014. *Multiple Sclerosis*, 6, 1515.
- Krishnan, S., Cairns, R., & Howard, R. (2009). Cannabinoids for the treatment of dementia. *The Cochrane Database of Systemic Reviews*. Apr 15;(2):CD007204. doi:10.1002/14651858.CD007204.pub2
- Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013). A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. *Journal of Neurology*, 260(4), 984-997.
- Large, M., Sharma, S., Compton, M. T., Slade, T., & Nielsen, O. (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. *Archives of General Psychiatry*, 68(6), 555-561.
- Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. *Psychological Medicine*, 44(4), 797-810.
- Linszen, D. H., Dingemans, P. M., & Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. *Archives of General Psychiatry*, 51(4), 273-279.
- Lopez-Quintero, C., de los Cobos, J. P., Hasin, D. S., Okuda, M., Wang, S., Grant, B. F., & Blanco, C. (2011). Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Drug and Alcohol Dependence*, 115(1), 120-130.
- Lu, M. L., & Agito, M. D. (2015). Cannabinoid hyperemesis syndrome: Marijuana is both antiemetic and proemetic. *Cleveland Clinic Journal of Medicine*, 82(7), 429-34.
- Lucas, P., Reiman, A., Earleywine, M., McGowan, S. K., Oleson, M., Coward, M. P., & Thomas, B. (2013). Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. *Addiction Research & Theory*, 21(5), 435-442.
- Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *American Family Physician*, 76, 391-6.
- Mackie, K. (2008). Cannabinoid receptors: Where they are and what they do. *Journal of Neuroendocrinology*, 20(Suppl 1), 10-41. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01671.x/full>
- Madras, B. (2015). *Update of cannabis and its medical use*. Retrieved from http://www.who.int/medicines/access/controlled-substances/6_2_cannabis_update.pdf
- Marijuana Policy Project. (2014). *Timeline of marijuana reform in the United States*. Retrieved from <https://www.mpp.org/federal/>
- Martín-Sánchez, E., Furukawa, T. A., Taylor, J., & Martin, J. L. R. (2009). Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Medicine*, 10(8), 1353-1368.
- Maust, D. T., Bonar, E. E., Ilgen, M. A., Blow, F. C., & Kales, H. C. (2016). Agitation in Alzheimer disease as a qualifying condition for medical marijuana in the United States. *The American Journal of Geriatric Psychiatry*, 24(11), 1000-1003.
- Mechoulam, R., & Burstein, S. H. (1973). *Marijuana: Chemistry, pharmacology, metabolism, clinical effects*. Academic Press.
- Mechoulam, R., Panikashvili, D., & Shohami, E. (2002). Cannabinoids and brain injury: Therapeutic implications. *Trends in Molecular Medicine*, 8(2), 58-61.
- Medical marijuana and epilepsy*. (2017). Epilepsy Foundation. Retrieved from <https://www.epilepsy.com/learn/treating-seizures-and-epilepsy/other-treatment-approaches/medical-marijuana-and-epilepsy>
- Meehan-Atrash, J., Luo, W., & Strongin, R. M. (2017). Toxicant formation in dabbing: The terpene story. *ACS Omega*, 2(9), 6112.
- Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., ... & Moffitt, T. E. (2012). Persistent cannabis users show neuro-psychological decline from childhood to midlife. *Proceedings of the National Academy of Sciences*, 109(40), E2657-E2664.
- Meiri, E., Jhangiani, H., Vredenburg, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., & Baranowski, V. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Current Medical Research and Opinion*, 23(3), 533-543.
- Melton, S. T. (June, 2017). *Stirring the pot: Potential drug interactions with marijuana*. Retrieved from www.medscape.com/viewarticle/881059?nlid=115679_785&src=WNL_mdplsfeat_170613_mscpedit_nurs&uac=226719HZ&spon=24&impID=1367261&faf=1
- Mikos, R. A. (2012, December 12). *On the limits of federal supremacy: When states relax (or abandon) marijuana bans*. Cato Institute. Policy Analysis, No. 714. Retrieved from <https://object.cato.org/sites/cato.org/files/pubs/pdf/PA714.pdf>
- Mikuriya, T. H. (2004). Cannabis as a substitute for alcohol: A harm-reduction approach. *Journal of Cannabis Therapeutics*, 4(1), 79-93.
- Moffat, B. M., Jenkins, E. K., & Johnson, J. L. (2013). Weeding out the information: An ethnographic approach to exploring how young people make sense of the evidence on cannabis. *Harm Reduction Journal*, 10(1), 34.
- Moitra, E., Christopher, P. P., Anderson, B. J., & Stein, M. D. (2015). Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults. *Psychology of Addictive Behaviors*, 29(3), 627.
- Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrop, T., & Emrich, H. M. (2002). Treatment of Tourette's syndrome with Δ^9 -tetrahydrocannabinol (THC): A randomized crossover trial. *Pharmacopsychiatry*, 35(02), 57-61.
- Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *The Journal of Pain*, 9(3), 254-264.
- National Academies of Sciences, Engineering, and Medicine. (2017). *The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research*. Washington, DC: National Academies Press.
- National Conference of State Legislatures. (2017). *State medical marijuana laws*. Retrieved from <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>
- National Institute on Drug Abuse. (2017, March). *NIDA's role in providing marijuana for research*. Retrieved from <https://www.drugabuse.gov/drugs-abuse/marijuana/nidas-role-in-providing-marijuana-research>
- National Institute on Drug Abuse. (2017, May). *Information on marijuana farm contract*. Retrieved from <https://www.drugabuse.gov/drugs-abuse/marijuana/nidas-role-in-providing-marijuana-research/information-marijuana-farm-contract>
- National Institutes of Health. (2018). *Drug information portal: Quick access to quality drug information*. Retrieved from <https://druginfo.nlm.nih.gov/drugportal/>
- New Jersey Department of Health. (2016). *The Department of Health Medicinal Marijuana Program 2016 Annual Report*. Retrieved from http://www.nj.gov/health/medicalmarijuana/documents/annual_report_2016.pdf
- Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. *Pain*, 133(1), 210-220.

- Ogu, C. C., & Maxa, J. L. (2000, October). Drug interactions due to cytochrome P450. *Proceedings (Baylor University. Medical Center)*, 13(4), 421.
- Omar, J., Olivares, M., Alzaga, M., & Erxebarria, N. (2013). Optimisation and characterisation of marihuana extracts obtained by supercritical fluid extraction and focused ultrasound extraction and retention time locking GC-MS. *Journal of Separation Science*, 36(8), 1397-1404.
- Pacher, P., Batkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacological Reviews* 58(3), 389-462. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/>
- Page, P. (2014). Beyond statistical significance: Clinical interpretation of rehabilitation research literature. *International Journal of Sports Physical Therapy*, 9(5), 726.
- Parfieniuk, A., & Flisiak, R. (2008). Role of cannabinoids in chronic liver diseases. *World Journal of Gastroenterology*, 14(40), 6109.
- Park, B., McPartland, J. M., & Glass, M. (2004). Cannabis, cannabinoids and reproduction. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 70(2), 189-197.
- Pergam, S. A., Woodfield, M. C., Lee, C. M., Cheng, G. S., Baker, K. K., Marquis, S. R., & Fann, J. R. (2017). Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. *Cancer*, 123(22), 4488-4497.
- Pooyania, S., Ethans, K., Szturm, T., Casey, A., & Perry, D. (2010). A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. *Archives of Physical Medicine and Rehabilitation*, 91(5), 703-707.
- ProCon.org. 29 legal medical marijuana states and DC. (2017, November 30). Retrieved from https://medicalmarijuana.procon.org/view_resource.php?resourceID=000881
- Reiman, A. (2009). Cannabis as a substitute for alcohol and other drugs. *Harm Reduction Journal*, 6(1), 35.
- Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*, 65(6), 812-819.
- Rosenberg, C. (2016a, August 12). *Applications to become registered under the Controlled Substances Act to manufacture marijuana to supply researchers in the United States*. Retrieved from <https://www.federalregister.gov/documents/2016/08/12/2016-17955/applications-to-become-registered-under-the-controlled-substances-act-to-manufacture-marijuana-to>
- Rosenberg, C. (2016b, August 12). *Denial of petition to initiate proceedings to reschedule marijuana*. Retrieved from <https://www.federalregister.gov/documents/2016/08/12/2016-17960/denial-of-petition-to-initiate-proceedings-to-reschedule-marijuana>
- Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015). Cannabinoids and epilepsy. *Neurotherapeutics*, 12(4), 747-768.
- Rough, L. (2017, June). *Leafly's state-by-state guide to cannabis testing regulations*. Retrieved from <https://www.leafly.com/news/industry/leafly-state-by-state-guide-to-cannabis-testing-regulations>
- Rubin, R. (2017). Medical marijuana is legal in most states, but physicians have little evidence to guide them. *JAMA*, 317(16), 1611-1613.
- Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364.
- Russo, E., & Guy, G. W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Medical Hypotheses*, 66(2), 234-246.
- Schoeler, T., Kambeitz, J., Behlke, I., Murray, R., & Bhattacharyya, S. (2016). The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. *Psychological Medicine*, 46(01), 177-188.
- Schuster, R. M., Hoepfner, S. S., Evins, A. E., & Gilman, J. M. (2016). Early-onset marijuana use is associated with learning inefficiencies. *Neuropsychology*, 30(4), 405.
- Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. *The Journal of Pain*, 9(2), 164-173.
- Smith, M. J., Cobia, D. J., Reilly, J. L., Gilman, J. M., Roberts, A. G., Alpert, K. I., ... & Csernansky, J. G. (2015). Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. *Hippocampus*, 25(9), 1042-1051.
- Söderpalm, A. H., Schuster, A., & de Wit, H. (2001). Antiemetic efficacy of smoked marijuana: Subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacology Biochemistry and Behavior*, 69(3), 343-350.
- Solowij, N., & Pesa, N. (2012). Cannabis and cognition: Short and long-term effects. *Marijuana and Madness*, 2, 91-102.
- Stockburger, S. (2016). Forms of administration of cannabis and their efficacy. *Journal of Pain Management*, 9(4), 381.
- Stout, S. M., & Cimino, N. M. (2014). Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. *Drug Metabolism Reviews*, 46(1), 86-95.
- Strouse, T. B. (2016). Cannabinoids in medical practice. *Alternative & Complementary Therapies*, 22(2).
- Svensden, K. B., Jensen, T. S., & Bach, F. W. (2004). Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. *BMJ*, 329(7460), 253.
- Tashkin, D. P. (2013). Effects of marijuana smoking on the lung. *Annals of the American Thoracic Society*, 10(3), 239-247.
- Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., ... & Gunning, B. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet*, 391(10125), 1085-1096.
- Thompson, G. R., Tuscano, J. M., Dennis, M., Singapuri, A., Libertini, S., Gaudino, R., ... & Engelthaler, D. M. (2017). A microbiome assessment of medical marijuana. *Clinical Microbiology and Infection*, 23(4), 269-270.
- Timpone, J. G., Wright, D. J., Li, N., Egorin, M. J., Enama, M. E., Mayers, J., & Galetto, G. (1997). The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. *AIDS Research and Human Retroviruses*, 13(4), 305-315.
- Tortoriello, G., Morris, C. V., Alpar, A., Fuzik, J., Shirran, S. L., Calvigioni, D., ... & Courtney, M. (2014). Miswiring the brain: Δ^9 -tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. *The EMBO Journal*, 33(7), 668-685.
- Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., ... & Namaka, M. (2015). Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: A randomized controlled trial. *Pain Medicine*, 16(1), 149-159.
- U.S. Department of Justice, Office of the Attorney General. (2018, January 4). *Marijuana enforcement*. Retrieved from <https://www.justice.gov/opa/press-release/file/1022196/download>

- U.S. Department of Justice, Office of Deputy Attorney General. (2011, June 29). *Guidance regarding the Ogden Memo in jurisdictions seeking to authorize marijuana for medical use*. Retrieved from <https://www.justice.gov/sites/default/files/oip/legacy/2014/07/23/dag-guidance-2011-for-medical-marijuana-use.pdf>
- U.S. Department of Justice, Office of Deputy Attorney General. (2013, February 14). *Guidance regarding marijuana related financial crimes*. Retrieved from <https://www.justice.gov/sites/default/files/usao-wdwa/legacy/2014/02/14/DAG%20Memo%20-%20Guidance%20Regarding%20Marijuana%20Related%20Financial%20Crimes%202%2014%20-%20282%29.pdf>
- U.S. Department of Justice, Office of Deputy Attorney General. (2013, August 29). *Guidance regarding marijuana enforcement*. Retrieved from <https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf>
- U.S. Department of Justice, Office of Executive Office for United States Attorneys. (2014, October 28). *Policy statement regarding marijuana issues in Indian country*. Retrieved from <https://www.justice.gov/sites/default/files/tribal/pages/attachments/2014/12/11/policystatementregardingmarijuanaissuesinindiancountry2.pdf>
- U.S. Department of Justice, Office of Public Affairs. (2009, October 19). *Attorney General announces formal medical marijuana guidelines*. Retrieved from <https://www.justice.gov/opa/pr/attorney-general-announces-formal-medical-marijuana-guidelines>
- U.S. Department of Transportation, National Highway Traffic Safety Administration. (2017). *Marijuana-impaired driving: A report to Congress*. Retrieved from <https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-report-to-congress.pdf>
- van Den Elsen, G. A., Ahmed, A. I., Verkes, R. J., Kramers, C., Feuth, T., Rosenberg, P. B., ... & Rikkert, M. G. O. (2015). Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. *Neurology*, *84*(23), 2338-2346.
- Vandrey, R., Raber, J. C., Raber, M. E., Douglass, B., Miller, C., & Bonn-Miller, M. O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. *JAMA*, *313*(24), 2491-2493.
- Vaney, C., Heinzl-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., ... & Reif, M. (2004). Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. *Multiple Sclerosis*, *10*(4), 417-424.
- Vergara, D., Bidwell, L. C., Gaudino, R., Torres, A., Du, G., Ruthenburg, T. C., ... & Kane, N. C. (2017). Compromised external validity: Federally produced cannabis does not reflect legal markets. *Scientific Reports*, *7*, 46528.
- Verweij, K. J., Zietsch, B. P., Lynskey, M. T., Medland, S. E., Neale, M. C., Martin, N. G., ... & Vink, J. M. (2010). Genetic and environmental influences on cannabis use initiation and problematic use: A meta-analysis of twin studies. *Addiction*, *105*(3), 417-430.
- Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. *New England Journal of Medicine*, *370*(23), 2219-2227.
- Wade, D. T., Collin, C., Stott, C., & Duncombe, P. (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. *Multiple Sclerosis Journal*, *16*(6), 707-714.
- Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Multiple Sclerosis Journal*, *10*(4), 434-441.
- Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clinical Rehabilitation*, *17*(1), 21-29.
- Wallace, M., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H. (2015). Efficacy of inhaled cannabis on painful diabetic neuropathy. *The Journal of Pain*, *16*(7), 616-627.
- Wallace, M., Schulteis, G., Atkinson, J. H., Wolfson, T., Lazzaretto, D., Bentley, H., ... & Abramson, I. (2007). Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *The Journal of the American Society of Anesthesiologists*, *107*(5), 785-796.
- Walsh, Z., Gonzalez, R., Crosby, K., Thiessen, M. S., Carroll, C., & Bonn-Miller, M. O. (2017). Medical cannabis and mental health: A guided systematic review. *Clinical Psychology Review*, *51*, 15-29.
- Ware, M. A., Fitzcharles, M. A., Joseph, L., & Shir, Y. (2010). The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial. *Anesthesia & Analgesia*, *110*(2), 604-610.
- Ware, M. A., Wang, T., Shapiro, S., Collet, J. P., Boulanger, A., Esdaile, J. M., ... & O'Connell, C. (2015). Cannabis for the management of pain: Assessment of safety study (COMPASS). *The Journal of Pain*, *16*(12), 1233-1242.
- Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., ... & Collet, J. P. (2010). Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. *Canadian Medical Association Journal*, *182*(14), E694-E701.
- Webster, G. B., & Sarna, L. P. (2002). U.S. Patent No. 6,403,126. Washington, DC: U.S. Patent and Trademark Office.
- Weier, M., & Hall, W. (2017). The use of cannabinoids in treating dementia. *Current Neurology and Neuroscience Reports*, *17*(8), 56.
- What is GRADE? (2012). *BMJ Best Practice*. Retrieved from <http://best-practice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/>
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., ... & Schmidkofer, S. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*, *313*(24), 2456-2473.
- Wilkinson, S. T., Radhakrishnan, R., & D'Souza, D. C. (2014). Impact of cannabis use on the development of psychotic disorders. *Current Addiction Reports*, *1*(2), 115-128.
- Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. *The Journal of Pain*, *14*(2), 136-148.
- Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008). A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *The Journal of Pain*, *9*(6), 506-521.
- Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. *Life Sciences*, *88*(15), 730-736.
- Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010). Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. *Biochemical Pharmacology*, *79*(11), 1691-1698.
- Yücel, M., Solowij, N., Respondek, C., Whittle, S., Fornito, A., Pantelis, C., & Lubman, D. I. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. *Archives of General Psychiatry*, *65*(6), 694-701.
- Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., ... & UK MS research group. (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. *The Lancet*, *362*(9395), 1517-1526.

- Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., Mattison, P. G., & MUSEC Research Group. (2012). Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. *Journal of Neurology, Neurosurgery & Psychiatry*, 83(11), 1125-1132.
- Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, 138(1), 103-141.